N-Octyl-β-valienamine up-regulates activity of F213I mutant β-glucosidase in cultured cells: a potential chemical chaperone therapy for Gaucher disease
- 1 August 2004
- journal article
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1689 (3) , 219-228
- https://doi.org/10.1016/j.bbadis.2004.03.007
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Chemical chaperones increase the cellular activity of N370S β-glucosidase: A therapeutic strategy for Gaucher diseaseProceedings of the National Academy of Sciences, 2002
- Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapyJournal of Inherited Metabolic Disease, 2001
- Improvement of neurological symptoms by enzyme replacement therapy for Gaucher disease type IIIbEuropean Journal of Pediatrics, 2001
- Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesisThe Lancet, 2000
- Accelerated transport and maturation of lysosomal α–galactosidase A in Fabry lymphoblasts by an enzyme inhibitorNature Medicine, 1999
- Enzyme therapy for Gaucher disease: the first 5 yearsBlood Reviews, 1998
- Prospective study of neurological responses to treatment with macrophage‐targeted glucocerebrosidase in patients with type 3 Gaucher's diseaseAnnals of Neurology, 1997
- Gaucher disease: Enzyme therapy in the acute neuronopathic variantAmerican Journal of Medical Genetics, 1997
- Synthesis of potent β-D-glucocerebrosidase inhibitors: N-alkyl-β-valienaminesBioorganic & Medicinal Chemistry Letters, 1996
- Replacement Therapy for Inherited Enzyme Deficiency — Macrophage-Targeted Glucocerebrosidase for Gaucher's DiseaseNew England Journal of Medicine, 1991